The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Genetic profiling analysis design of well-differentiated aggressive grade 2 and 3 gastroenteropancreatic neuroendocrine tumors in the phase III randomized controlled COMPOSE trial.
 
Thorvardur Ragnar Halfdanarson
Consulting or Advisory Role - Advanced Accelerator Applications (Inst); Crinetics Pharmaceuticals (Inst); Ipsen (Inst); ITM Isotope Technologies Munich (Inst); Tersera; TERUMO; Viewpoint Molecular Targeting (Inst)
Research Funding - Advanced Accelerator Applications (Inst); Agios (Inst); Basilea (Inst); Ipsen (Inst); Novartis (Inst); Thermo Fisher Scientific (Inst); Turnstone Bio (Inst)
 
Jaume Capdevila
Consulting or Advisory Role - Advanced Accelerator Applications; Bayer; Eisai; Esteve; Exelixis; Ipsen; Isotopen Technologien; Lilly; Merck Serono; Novartis; Pfizer; Roche/Genentech; Sanofi
Speakers' Bureau - Bayer; Eisai; Esteve; Hutchison MediPharma; Ipsen; Isotopen Technologien; Lilly; Merck Serono; Novartis; Pfizer; Sanofi
Research Funding - Advanced Accelerator Applications (Inst); AstraZeneca (Inst); Bayer (Inst); Eisai (Inst); Ipsen (Inst); Ipsen (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Eisai; Ipsen; Pfizer
 
Daniel M. Halperin
Consulting or Advisory Role - Advanced Accelerator Applications; Camurus; Chimeric Therapeutics; Crinetics Pharmaceuticals; Curium Pharma; Ipsen; Isotopen Technologien; Lexicon; Novartis; Progenics; Radiomedix; Tersera
Research Funding - Advanced Accelerator Applications (Inst); Genentech/Roche (Inst); Isotopen Technologien (Inst); Tarveda Therapeutics (Inst); Thermo Fisher Scientific (Inst)
 
Ken Herrmann
Leadership - Pharma15; SOFIE; Theragnostics
Stock and Other Ownership Interests - Aktis Oncology; Pharma15; SOFIE; Theragnostics
Consulting or Advisory Role - Advanced Accelerator Applications; Amgen; Bain Capital; Bayer; BTG; GE Healthcare; IPSEN; ITG (Inst); Novartis; ROTOP Pharmaka (Inst); Siemens Healthineers
 
Grace Kong
Consulting or Advisory Role - ITM Oncologics
Speakers' Bureau - Ipsen; SAM Nordic
Research Funding - Cyclotek; ITM Oncologics (Inst); Pfizer
 
Simone Leyden
Consulting or Advisory Role - ITM Oncologics
 
Josh Mailman
Stock and Other Ownership Interests - Abbott Laboratories; Anthem; AstraZeneca; DANAHER; Dexcom; LabCorp; Medtronic; Novo Nordisk; Sanofi; Thermo Fisher Scientific; Veeva Systems
Honoraria - Ipsen; Novartis
Consulting or Advisory Role - Camurus; Crinetics Pharmaceuticals; ITM Oncologics; RayzeBio
 
Diane Reidy-Lagunes
Honoraria - Novartis
Consulting or Advisory Role - Advanced Accelerator Applications; Chiasma; ITM Oncologics; Lexicon
Research Funding - Ipsen; Merck; Novartis
 
Rajaventhan Srirajaskanthan
Consulting or Advisory Role - Ipsen; ITM Oncologics; Novartis
Speakers' Bureau - Ipsen; ITM Oncologics; Novartis
Travel, Accommodations, Expenses - Ipsen
 
Máté Erdö
Employment - ITM Oncologics
Honoraria - ITM Oncologics
Consulting or Advisory Role - ITM Oncologics
Travel, Accommodations, Expenses - ITM Oncologics
 
Amanda Rotger
Employment - ITM Oncologics
Honoraria - ITM Oncologics
Consulting or Advisory Role - ITM Oncologics
Travel, Accommodations, Expenses - ITM Oncologics
 
Thomas Thevenet
Stock and Other Ownership Interests - Amylyx; Clarity Pharmaceuticals; Novartis; Sanofi; Telix Pharmaceuticals
Consulting or Advisory Role - In3Bio; ITM Oncologics; NVision
Research Funding - ITM Oncologics